A phase I study of ZGN-1258 for Prader-Willi Syndrome
Latest Information Update: 21 Sep 2020
At a glance
- Drugs ZGN-1258 (Primary)
- Indications Prader-Willi syndrome
- Focus Adverse reactions
- 07 Nov 2018 According to a Zafgen media release, the company expects to initiate this trial in the the first quarter of 2019.
- 08 May 2018 According to a Zafgen media release, the company expects to initiate this trial in the fourth quarter of 2018.
- 08 Feb 2018 According to a Zafgen media release, the company plans to file an investigational new drug (IND) application with the U.S. FDA in 2018.